TGOD01

Active money manager trading equities, futures and options for over 30 years. Day- and swing-trades.

[TGOD01 @tgod01]

@BDC_Analyst More natural buyers :) Combine this with the shorts that are under water - there are alot of folks looking to buy stock. +++

[TGOD01 @tgod01]

@AnnaFlorcia $INSM is quickly reverting to mean as the previous promises are already unraveling (see crumbling Brinsupri growth story). Those ignoring the math in their latest earnings call are feeling ALOT of pain. Can see these market caps crossing paths in the not too distant future.

[TGOD01 @tgod01]

@AnnaFlorcia Your assessment is correct. The shorts identify the air pockets and take full advantage. Annoying, but part of the game. This too shall pass.

[TGOD01 @tgod01]

$LQDA I'm sure RJ and Mike will have nothing good to say at Jefferies tomorrow

[TGOD01 @tgod01]

$LQDA been expecting one of these fugly days since the big run up. Even completely sh*t the bed into the close. Nice. It needed a big shake to firm up the base - some backing and filling will do it good. Will be interesting to see how long it trades heavy. Guessing not long

[TGOD01 @tgod01]

$LQDA finally taking a breather today. Way overdue. And constructive. Stay the course.

[TGOD01 @tgod01]

$LQDA As soon as people start to get their head around what real peak sales could be (COO Kaseta mentioned $3-5 billion today -hell, even $2B) - the share price equation dramatically changes. People then realize how ridiculously undervalued this stock is.

[TGOD01 @tgod01]

Quick correction - UTC is only doing $1.8-1.9B with Tyvaso, but I'd add - the TAM estimates for PH-ILD are significantly undersized due to lack of effective treatments and market penetration (<20%). That market alone could be as high as $10B. And with Yutrepia showing strong efficacy in that indication - they will own it. So peak sales of $4B peak revenue is not pie-in-the-sky - it's definitely doable.

[TGOD01 @tgod01]

@insiderbaba Per pre-arranged stock sale plan put in place in Nov 2025. Yawn.

[TGOD01 @tgod01]

$INSM files mixed shelf offering on a late Friday afternoon. This after a 50%+ drop in share price over the past 5 months. I thought good management raised at the top, not at the supposed bottom so many are panting about? Screams so much confidence. #yikes

[TGOD01 @tgod01]

$LQDA short interest finally dropped below 10M in the latest data as of 4/30. Expect another big drop for the 5/15 update. Proof that even fish can learn.

[TGOD01 @tgod01]

$LQDA this is what the action looks like when you are clearly winning the war $LQDA

[TGOD01 @tgod01]

$LQDA Since today was a bit of a watershed day - I'll chime in. First off - congrats to all fellow LQDA longs! Dont know about you, but my retirement plan took a huge step forward today lol

The earnings report was everything I thought it would be and more. The acceleration in the patient adds was very encouraging - especially considering there is still some legal overhang looming (which I'll reiterate - there is nothing to worry about).

But being north of 50 while still waiting for the ruling was something I didnt really expect. At the same time, this bodes extremely well for the near term. At this point, the entire script almost flips from - many being worried about being in when the ruling hits - to now those are worried of being out when the ruling hits. Seems many are coming more and more to grips with the idea that the legal ruling will be a clean sweep for Liquidia - and now the fear is more of missing out on the pop when it hits vs any potential drop on a now extremely unlikely negative ruling.

Couple all this with the 11M shorts that are feeling some serious pinch (most are short from the high teens, btw) - and we have alot of natural buyers up here in the previously considered stratosphere. Not saying we wont have some back and fill, but today - we have reset the trading range quite a bit higher. And I'm diggin it...

[TGOD01 @tgod01]

$LQDA @meremrtl you've been so right all along on LQDA! Thank you for your valuable insight! 🤡🤡🤡

[TGOD01 @tgod01]

@_Ceiv Your timing is impeccable once again. 🤡

[TGOD01 @tgod01]

$INSM knife catchers getting slaughtered over the last couple of months. Be careful who you listen to

[TGOD01 @tgod01]

$LQDA $UTHR the smoke and mirrors clown show continues at United Therapeutics. Martine is no longer "super pumped" like she was in the last call, but she did say UT is doing "frickin amazing" LOL Consummate professional 🤡

Interestingly - while on their last earnings call in early February - while they were making excuses about the Tyvaso shortfall then - they mentioned things had really picked up in February - and also said they would return to sequential growth in Q2. All this while saying the competitive product (Yuterpia) had seen it's market introductory spike and interest was now waning. Yeah. Right.

Fast forward to this morning - it's the same story, only worse. While making excuses about Tyvaso's shortfall again - blaming severe weather (mildest US winter in years, btw) and seasonality (even though their last 3 Q1's have been significantly, sequentially higher) - they pointed to February being a tough month (but you said in the previous call that Feb was ramping??). Not only had things not ramped, they had what appears to be a Tyvaso inventory write-down (veiled in some jargonized mumbo jumbo) to the tune of $26.8M. Yikes

Additionally, they are now saying we expect a return to sequential growth "in the near term" - no longer Q2. So I wouldnt expect that revenue bar chart they always show to turn up any time soon.

Bottom line - Yutrepia is most assuredly kicking Tyvaso's ass - and that trend is not going to stop. Cannot wait for RJ & co. to spell it all out next Monday. Long and extremely strong $LQDA